TEVA-LIOTHYRONINE DIN 02494337
Status: Marketed
Holder: TEVA CANADA LIMITED
Molecule: LIOTHYRONINE (LIOTHYRONINE SODIUM)
Available to quote
Health Canada record
| Active ingredient(s) | LIOTHYRONINE (LIOTHYRONINE SODIUM) 5 MCG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | H03AA02 LIOTHYRONINE SODIUM |
| Original market date | 10-Jul-2020 |
| Current status date | 10-Jul-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LIOTHYRONINE (LIOTHYRONINE SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02549999 | AURO-LIOTHYRONINE | AURO PHARMA INC | Tablet | LIOTHYRONINE (LIOTHYRONINE SODIUM) 5 MCG | Marketed |
| 02550008 | AURO-LIOTHYRONINE | AURO PHARMA INC | Tablet | LIOTHYRONINE (LIOTHYRONINE SODIUM) 25 MCG | Marketed |
| 01919458 | CYTOMEL | PFIZER CANADA ULC | Tablet | LIOTHYRONINE (LIOTHYRONINE SODIUM) 5 MCG | Marketed |
| 01919466 | CYTOMEL | PFIZER CANADA ULC | Tablet | LIOTHYRONINE (LIOTHYRONINE SODIUM) 25 MCG | Marketed |
| 02494345 | TEVA-LIOTHYRONINE | TEVA CANADA LIMITED | Tablet | LIOTHYRONINE (LIOTHYRONINE SODIUM) 25 MCG | Marketed |
| 02561301 | ZDS-LIOTHYRONINE | ZYDUS LIFESCIENCES LIMITED | Tablet | LIOTHYRONINE (LIOTHYRONINE SODIUM) 25 MCG | Marketed |
| 02561298 | ZDS-LIOTHYRONINE | ZYDUS LIFESCIENCES LIMITED | Tablet | LIOTHYRONINE (LIOTHYRONINE SODIUM) 5 MCG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 22930 | 2019-11-21 | Abbreviated New Drug Submission (ANDS) |